Literature DB >> 20590915

Novel amelanotic and melanotic cell lines NM78-AM and NM78-MM derived from a human oral malignant melanoma.

Taka Nakahara1, Yuichi Tamaki, Noriko Tominaga, Yoshiaki Ide, Masanori Nasu, Akihiro Ohyama, Soh Sato, Isamu Ishiwata, Hiroshi Ishikawa.   

Abstract

Abstract Novel cell lines, designated NM78-AM and NM78-MM, have been established from a malignant melanoma of the cheek oral mucosa. NM78-AM cells were spherical, grew in suspension as clusters, and produced no melanin. In contrast, NM78-MM cells were adherent and produced melanin granules. Initially, NM78-AM cells were grown on fibroblast feeder cells or in growth media supplemented with 10% conditioned medium from fibroblasts, but eventually grew in standard growth media alone. NM78-AM cells had interdigitating microvilli and formed cell clusters. They had large nucleoli, desmosomes, lipid droplets, and well-developed Golgi apparatuses. In contrast, NM78-MM cells grew as adherent neuron-like cells. They had large prominent nucleoli, irregular nuclear membranes, a number of mitochondria, well-developed Golgi apparatuses, melanosomes at various stages of development in the cytoplasm, and the cells secreted melanin granules. Projections from these melanotic cells formed anastomoses with each other. NM78-MM cells stained immunofluorescently for internexin, neuron specific enolase, NF-200, and glial fibrillary acidic protein. These cells were severely aneuploid, approximating to triploidy, and had many marker chromosomes. We used a real-time monitoring system to evaluate oxygen concentrations in culture medium to investigate the susceptibility of both cell lines to various anti-cancer drugs. NM78-AM cells were slightly sensitive to actinomycin D, but not to cisplatin, irinotecan, the irinotecan metabolite SN-38, taxol, taxotere, bleomycin and methotrexate; NM78-MM cells were sensitive to cisplatin, and not to taxol, taxotere, carboplatin, and irinotecan. These new cell lines, NM78-AM and NM78-MM, will be very important for the development of new chemotherapeutics for oral malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20590915     DOI: 10.1111/j.1749-0774.2009.00079.x

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  17 in total

Review 1.  Induction of the neural crest: a multigene process.

Authors:  Anne K Knecht; Marianne Bronner-Fraser
Journal:  Nat Rev Genet       Date:  2002-06       Impact factor: 53.242

Review 2.  Measuring respiration of cultured cell with oxygen electrode as a metabolic indicator for drug screening.

Authors:  Y Amano; C Okumura; M Yoshida; H Katayama; S Unten; J Arai; T Tagawa; S Hoshina; H Hashimoto; H Ishikawa
Journal:  Hum Cell       Date:  1999-03       Impact factor: 4.174

3.  Establishment and characterization of primary and metastatic uveal melanoma cell lines.

Authors:  G P Luyten; N C Naus; C M Mooy; A Hagemeijer; J Kan-Mitchell; E Van Drunen; V Vuzevski; P T De Jong; T M Luider
Journal:  Int J Cancer       Date:  1996-05-03       Impact factor: 7.396

4.  Electron microscopic and cytochemical observations of theophylline and melanocyte-stimulating hormone effects on melanoma cells in culture.

Authors:  F Hu; K Mah; D J Teramura
Journal:  Cancer Res       Date:  1982-07       Impact factor: 12.701

5.  [Establishment and characterization of a human cell line, HS-MM, derived from a case of clear cell sarcoma].

Authors:  H Sonobe; Y Manabe; M Furihata; J Iwata; T Hikita; T Tanimoto; O Kiuna; T Oka; Y Ohtsuki; H Mizobuchi
Journal:  Hum Cell       Date:  1990-12       Impact factor: 4.174

6.  [A newly established melanoma cell line (GAK) with 5-S-cysteinyldopa phenotype].

Authors:  S Nozawa; H Ohta; K Tsukazaki; Y Udagawa; S Kurihara; S Kano
Journal:  Nihon Sanka Fujinka Gakkai Zasshi       Date:  1984-06

7.  Establishment and characterization of melanoma cell line derived from malignant melanoma of human uterine cervix.

Authors:  K Kiguchi; I Ishiwata; C Ishiwata; Y Tokieda; M Iguchi; R Suzuki; M Saga; H Ishikawa
Journal:  Hum Cell       Date:  1998-06       Impact factor: 4.174

8.  Primary malignant melanoma of the oral cavity. Case report and establishment of melanoma cell line.

Authors:  T Tagawa; R Yatani; H Nishioka; M Murata
Journal:  Int J Oral Surg       Date:  1981

9.  Malignant oral tumours in Sweden 1960-1989--an epidemiological study.

Authors:  J Ostman; G Anneroth; H Gustafsson; B Tavelin
Journal:  Eur J Cancer B Oral Oncol       Date:  1995-03

10.  Establishment and characterization of a cell line (DEOC-1) originating from a human malignant melanoma of the skin.

Authors:  Seiji Maeshima; Takashi Yamada; Kimihiro Kiyokane; Hiroshi Mori
Journal:  Hum Cell       Date:  2007-05       Impact factor: 4.174

View more
  5 in total

1.  In vitro analysis of mesenchymal stem cells derived from human teeth and bone marrow.

Authors:  Yuichi Tamaki; Taka Nakahara; Hiroshi Ishikawa; Soh Sato
Journal:  Odontology       Date:  2012-07-07       Impact factor: 2.634

2.  Isolation and characterization of vascular endothelial cells derived from fetal tooth buds of miniature swine.

Authors:  Masanori Nasu; Taka Nakahara; Noriko Tominaga; Yuichi Tamaki; Yoshiaki Ide; Toshiaki Tachibana; Hiroshi Ishikawa
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-02-22       Impact factor: 2.416

Review 3.  Interdigitating dendritic cell sarcoma: analysis of two original extra-nodal cases and review of literature.

Authors:  Jiayu Zhou; Qingling Li; Xiaodan Fu; Deyun Feng; Keda Yang; Junpu Wang
Journal:  Virchows Arch       Date:  2022-04-09       Impact factor: 4.064

4.  Practical methods for handling human periodontal ligament stem cells in serum-free and serum-containing culture conditions under hypoxia: implications for regenerative medicine.

Authors:  Dai Murabayashi; Mai Mochizuki; Yuichi Tamaki; Taka Nakahara
Journal:  Hum Cell       Date:  2017-02-06       Impact factor: 4.174

5.  Paclitaxel-loaded star-shaped copolymer nanoparticles for enhanced malignant melanoma chemotherapy against multidrug resistance.

Authors:  Yongsheng Su; Jian Hu; Zhibin Huang; Yubin Huang; Bingsheng Peng; Ni Xie; Hui Liu
Journal:  Drug Des Devel Ther       Date:  2017-03-06       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.